Table 1:
Baseline characteristics (per-protocol population)
| 100 mg (n=8) | 300 mg (n=7) | 1000 mg (n=6) | 2000 mg (n=8) | All groups (n=29) | |
|---|---|---|---|---|---|
| General characteristics | |||||
| Age, years | |||||
| Mean (SD) | 62·9 (8·6) | 62·1 (12·2 | 66·7 (11·6) | 50·9 (11·B) | 60·2 (12·1) |
| Median (IQR) | 64·0 (55·8–69·0) | 60·0 (54·5–70·5) | 6B·0 (59·3–74·5) | 46·5 (41·3–63·3) | 62·0 (50·0–70·0) |
| Sex | |||||
| Male | 8 (l00%) | 7 (100%) | 6 (100%) | 7 (87·5%) | 2B (96·6%) |
| Female | 0 | 0 | 0 | 1 (12·5%) | 1 (3·4%) |
| BMI, kg/m2 | |||||
| Mean (SD) | 28·5 (2·0) | 28·l (3·5) | 28·7 (3·3) | 29·1 (4·0) | 2B·6 (3·1) |
| Median (IQR) | 28·7 (27·4–29·9 | 27·7 (27·1–29·4) | 29·0 (27·9–30·7) | 27·7 (26·2–32·1) | 28·l (26·7–30·9 |
| SBP, mm Hg | |||||
| Mean (SD) | 136·6 (11·4) | 142·0 (16·5) | 128·7 (15·4) | 149·3 (17·3) | 139·8 (16·2) |
| Median (IQR) | 134·0 (130·0–139·3) | 136·0 (135·0–147·0) | 129·5 (122·3–136·0) | 141·5 (137·5–159·8) | 136·0 (131·0–145·0) |
| DBP, mm Hg | |||||
| Mean (SD) | 83·5 (10·0) | 90·6 (9·3) | 80·5 (5·0) | 92·3 (16·1) | 87·0 (11·7) |
| Median (IQR) | 82·5 (76·0–88·8) | 90·0 (84·5–96·0) | 80·0 (78·5–80·0) | 86·0 (79·0–104·0) | 82·0 (79·0–94·0) |
| Duration from gout flare to treatment, h | |||||
| Mean (SD) | 63·1 (16·9) | 33·3 (15·9) | 58·3 (20·7) | 45·0 (29·2) | 49·9 (23·6) |
| Median (IQR) | 66·5 (53·5–74·5) | 34·0 (15·0–51·0) | 53·0 (42·0–83·0) | 35·5 (23·5–69·5) | 52·0 (31·0–68·0) |
| Affected joint | |||||
| MTP1 | 5 (62·5%) | 4 (57·1%) | 4 (66·7%) | 7 (87·5%) | 20 (69·0%) |
| Ankle | 3 (37·5%) | 3 (42·9%) | 1 (16·7%) | 0 | 7 (24·1%) |
| Knee | 0 | 0 | 1 (16·7%) | 1 (12·5%) | 2 (6·9%) |
| Laboratory measurements | |||||
| Serum uric acid, pmol/L | |||||
| Mean (SD) | 399 (108) | 439 (159) | 403 (217) | 444 (54) | 422 (134) |
| Median (IQR) | 440 (298–465) | 500 (295–535) | 420 (263–518) | 460 (413–483) | 450 (330–500) |
| CRP, mg/L | |||||
| Mean (SD) | 30·5 (63·8) | 19·6 (16·3) | 22·8 (31·2) | 11·1 (8·6) | 20·9 (36·4) |
| Median (IQR) | 8·8 (3·9–14·5) | 15·0 (7·1–33·0) | 10·1 (7·7–17·0) | 10·8 (4·4–14·5) | 11·0 (5·9–17·0) |
| SAA, mg/L | |||||
| Mean (SD) | 228·5 (614·9) | 49·3 (63·9) | 96·2 (192·7) | 15·3 (14·1) | 99·0 (330·9) |
| Median (IQR) | 10·1 (3·0–25·2) | 29·7 (11·3–51·0) | 23·2 (8·5·30·6) | 10·9 (7·0–19·2) | 16·3 (6·7–29·7) |
| eGFR (MDRD), mL/min per 173m2 | |||||
| Mean (SD) | 68·8 (9·2) | 59·6 (9·5) | 70·0 (11·1) | 83·4 (9·7) | 70·9 (12·8) |
| Median (IQR) | 68·6 (65·6–70·0) | 59·1 (56·7–65·0) | 75·0 (67·3–75·9) | 83·3 (75·3–92·3) | 71·2 (64·8–76·5) |
| HbAlc, mmol/mol | |||||
| Mean (SD) | 40·3 (6·0) | 39·9 (7·0) | 38·2 (11·1) | 35·9 (6·2) | 38·5 (7·4) |
| Median (IQR) | 38·0 (36·5–44·0) | 40·0 (34·0–45·5) | 31·5 (31·0–46·3) | 35·0 (32·5–36·3) | 36·0 (33·0–44·0) |
| Comorbidities | |||||
| Hypertension | 6 (75·0%) | 4 (57·1%) | 5 (83·3%) | 5 (62·5%) | 20 (69·0%) |
| Cardiovascular diseases | 2 (25·0%) | 4 (57·1%) | 4 (66·7%) | 1 (12·5%) | 11 (37·9%) |
| Diabetes | 2 (25·0%) | 1 (14·3%) | 2 (33·3%) | 0 | 4 (13·8%) |
| Clinical scores | |||||
| Pain score | |||||
| Mean (SD) | 64·1 (9·6) | 70·6 (5·9) | 82·2 (14·8) | 68·9 (9·5) | 70·7 (11·6) |
| Median (IQR) | 63·0 (57·0–73·5) | 71·0 (68·0–74·0) | 82·5 (73·0–95·0) | 70·5 (51·0–80·0) | 71·0 (61·0–76·0) |
| General disability | |||||
| Mean (SD) | 62·8 (18·1) | 63·6 (27·8) | 60·7 (24·5) | 68·3 (16·2) | 64·0 (20·7) |
| Median (IQR) | 65·5 (50·0–77·0) | 73·0 (43·0–78·0) | 66·0 (52·0–75·0) | 72·5 (53·0–77·5) | 71·0 (52·0–76·0) |
| Walking disability | |||||
| Mean (SD) | 71·9 (18·5) | 70·3 (14·7) | 79·5 (31·4) | 73·0 (20·1) | 73·4 (20·5) |
| Median (IQR) | 79·5 (65·0–82·5) | 71·0 (60·0–80·0) | 91·5 (75·0–100·0) | 80·5 (61·5–88·5) | 79·0 (60·0–88·0) |
BMI=body-mass index. CRP=C-reactive protein. DBP=diastolic blood pressure. eGFR=estimated glomerular filtration rate. HbA1c=glycated haemoglobin. MDRD=modification of diet in renal disease. MTP1=first metatarsophalangeal. SAA=serum amyloid A. SBP=systolic blood pressure.